BioPorto A/S (CPH:BIOPOR)
Denmark · Delayed Price · Currency is DKK 1.175
0.00 (0.00%)
Sep 11, 2026, 3:18 PM CET
BioPorto Financials Overview
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 38.37 | 40.29 | 36.24 | 30.96 | 28.97 | 24.25 |
Revenue Growth | 7.06% | 11.16% | 17.07% | 6.87% | 19.44% | 4.52% |
Gross Profit Gross Profit Growth | 29.5 | 30.39 | 24.53 | 20.18 | 19.04 | 15.04 |
Operating Income Operating Income Growth | -13.66 | -78.39 | -72.05 | -60.16 | -78.94 | -65.26 |
Net Income Net Income Growth | -17.97 | -82.12 | -68.24 | -56.33 | -75.92 | -57.11 |
Earnings Per Share EPS Growth | -0.03 | -0.15 | -0.17 | -0.16 | -0.24 | -0.21 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
NGAL Tests NGAL Tests Growth | 28.48 | 28.22 | 23.05 | 18.56 | 14.86 | 12.35 |
Antibodies Antibodies Growth | 8.51 | 10.54 | 10.78 | 10.68 | 12.03 | 9.29 |
ELISA Kits ELISA Kits Growth | 1.26 | 1.38 | 2.27 | 1.67 | 1.84 | 2.55 |
Royalty and Other Royalty and Other Growth | 0.12 | 0.15 | 0.14 | 0.05 | 0.24 | 0.06 |
Total Total Growth | 38.37 | 40.29 | 36.24 | 30.96 | 28.97 | 24.25 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 74.44 | 54.89 | 59.66 | 66.4 | 81.79 | 45.52 |
Total Debt Total Debt Growth | 5.83 | 7.52 | 11.19 | 7.25 | 10.65 | 13.03 |
Net Cash (Debt) Net Cash Growth | 68.61 | 47.37 | 48.47 | 59.15 | 71.15 | 32.49 |
Net Cash Growth | 77.63% | -2.27% | -18.05% | -16.86% | 118.99% | -66.60% |
Net Cash Per Share Net Cash Per Share Growth | 0.12 | 0.09 | 0.12 | 0.17 | 0.22 | 0.12 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -72.65 | -77.07 | -83.58 | -55.46 | -52.49 | -64.58 |
Capital Expenditures CapEx Growth | 1.37 | - | -0.35 | -0.04 | -0.41 | -0.13 |
Free Cash Flow Free Cash Flow Growth | -71.28 | -77.07 | -83.93 | -55.5 | -52.89 | -64.71 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 76.88% | 75.44% | 67.68% | 65.19% | 65.73% | 62.01% |
Operating Margin | -35.59% | -194.59% | -198.80% | -194.34% | -272.51% | -269.05% |
Pretax Margin | -56.02% | -217.53% | -203.47% | -197.71% | -281.50% | -263.21% |
Profit Margin | -46.83% | -203.83% | -188.29% | -181.95% | -262.08% | -235.48% |
FCF Margin | -185.77% | -191.29% | -231.58% | -179.26% | -182.58% | -266.79% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 15.16 | 12.54 | 18.38 | 25.63 | 26.75 | 27.27 |